Increasing Prevalence of Batten Disease to boost Batten Disease Treatment Market Growth

 

Batten Disease Treatment Market, By Types (Congenital NCL, Infantile NCL, Late Infantile NCL and Adult NCL), Drugs (Cerliponase Alfa, Valproic Scid and Levetiracetam), Therapy (Occupational Therapy and Physical Therapy), Treatment (Medication and Supportive Care), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), End Users (Hospitals, Homecare, Specialty Clinics and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) Size, Share, Outlook, and Opportunity Analysis, 2023-2030

The global Batten Disease Treatment Market is estimated to be valued at reach US$ 41.39 million in 2023 and is expected to exhibit a CAGR of 2.79 % over the forecast period, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Batten Disease is known to be a very dangerous disease that affects the nervous system and the problem starts initially from childhood. The indications of the symptoms that are related to batten disease start being exposed from the age of 5 to 10 years. Usually, it is referred to as autosomal recessive, it is the general name for a category of disorders which come under the category of NCLs.

Competitive Landscape:

Key players involved in the growth of global Batten Disease Treatment Market are Teva Pharmaceutical Industries Ltd, Neurogene, Sun Pharmaceutical Industries Ltd, Pfizer Inc, Polaryx, Abeona Therapeutics Inc, Mylan N.V., STEMCELL Technologies Inc, Fresenius Kabi AG, Evotec SE, Zydus Cadila, AbbVie Inc, Spark Therapeutics, Inc, Regenxbio Inc, BioMarin, Amicus Therapeutics, Inc, Lilly, Bayer AG, Novartis AG,

Market Key Drivers:

Increasing prevalence of batten disease is expected to boost the growth of the global Batten Disease Treatment Market. For instance, as per the facts and figures around 14, 000 children across the globe suffer from batten disease.

Rising neurological diseases is anticipated to drive the growth of global Batten Disease Treatment Market. For instance, as per PAHO in 2019 around 533,172 people died due to neurological diseases in 2019.

Covid-19 Impact Analysis:

The Covid-19 outbreak has adversely affected the growth of the global Batten Disease Treatment Market due to the restrictions imposed by regulations, less visits of patients to hospitals. The trade market was interrupted during the period, and this impeded the neurological drug supply chain. The decrease in biopsies and postponement in surgeries associated to respective diseases impacted the market growth.

Key Takeaways:

The global Batten Disease Treatment Market is anticipated to exhibit a CAGR of 2.79 % during the forecast period due to strict regulatory policies and investments. For instance, US invested over US$ 10,000 per person, which is the highest medical expenditure globally.

Among regions, North America, Europe, and Asia Pacific are expected to witness robust growth in the global Batten Disease Treatment Market due to rising prevalence of batten disease, increasing neurological diseases, growing government policies and strict rules. For instance, as per the NIH, around 3 out of 100,000 people suffer from batten disease in U.S.